Overview

Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.
Details
Lead Sponsor:
University of California, San Diego
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Lithium Carbonate
Valproic Acid